Larvol Veri

BIOMARKER:

POLE mutation

Entrez ID:

5426

Related biomarkers:

Mutation

‹

›

POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
POLE mutation POLE mutation	Gastric Cancer Gastric Cancer	CP-675206 Sensitive: C2 – Inclusion Criteria CP-675206 Sensitive : C2
POLE mutation POLE mutation	Gastric Cancer Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
POLE mutation POLE mutation	Solid Tumor Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLE mutation POLE mutation	Solid Tumor Solid Tumor	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2
POLE mutation POLE mutation	Melanoma Melanoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Colorectal Cancer CRC	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Melanoma Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Colorectal Cancer CRC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Melanoma Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Colorectal Cancer CRC	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES